Breaking News

PAREXEL Appoints Imaging VP

April 14, 2014

Steiger brings 25 years of experience

Peter Steiger, Ph.D., has been appointed to the newly created position of vice president and chief scientific officer for Medical Imaging at PAREXEL. Dr. Steiger has more than 25 years of experience in specialized medical imaging techniques to support drug development. He will oversee the worldwide medical imaging scientific strategy at PAREXEL Informatics, which provides technology solutions to help facilitate the clinical development process.
 
Prior to joining the company, Dr. Steiger was chief executive officer of Optasia Medical from 2006 to 2013 and chief executive officer of Synarc from 2000 to 2005. He also served as chief scientist for Hologic, where he led the medical data management division responsible for supporting the use of bone densitometry measurements in clinical studies.   
 
"Peter Steiger's proven industry track record and deep musculoskeletal imaging expertise make him an outstanding addition to our medical imaging team," said Xavier Flinois, president of PAREXEL Informatics. "Clinical study sponsors increasingly rely on medical imaging technologies as surrogate endpoints to quickly assess safety and efficacy for 'go/no-go' pipeline decision-making. Peter's appointment reflects our ongoing commitment to leveraging global industry expertise to advance our client's innovative pipelines and fully support them through their complex drug development journey."

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity